A phase I/II dose finding study evaluating the safety and tolerability of capecitabine and aflibercept in patients with unresectable metastatic colorectal cancer deemed unsuitable for doublet/triplet chemotherapy: results of the phase I study
Authors
Ross, PRepana, D
Saunders, Mark P
Wilson, R
Plummer, C
Summers, J
Higgins, F
Peacock, J
Harari, D
Bridgewater, J
Affiliation
Guys and St Thomas' NHS FT, Oncology, LondonIssue Date
2017-02
Metadata
Show full item recordCitation
A phase I/II dose finding study evaluating the safety and tolerability of capecitabine and aflibercept in patients with unresectable metastatic colorectal cancer deemed unsuitable for doublet/triplet chemotherapy: results of the phase I study 2017, 72:S69 European Journal of CancerJournal
European Journal of CancerDOI
10.1016/S0959-8049(17)30306-4Additional Links
http://linkinghub.elsevier.com/retrieve/pii/S0959804917303064Type
Meetings and ProceedingsLanguage
enISSN
09598049ae974a485f413a2113503eed53cd6c53
10.1016/S0959-8049(17)30306-4